BriaCell Therapeutics Corp. (BCTX) shares were trading at $10.61, up 39.06% or $2.98 higher, following news of a sustained complete resolution of a lung metastasis in a metastatic breast cancer patient treated with the company's Bria-OTS personalized immunotherapy in an ongoing Phase 1/2a study.
The response was confirmed at multiple timepoints through 11 months of follow-up and was reported without treatment-limiting toxicities, strengthening confidence in the therapeutic potential of the Bria-OTS platform.
On the announcement day, BCTX opened near the prior session's close, rallied to intraday highs well above $10, and maintained elevated trading levels throughout the session as investor interest spiked around this clinical milestone. The stock trades on the NasdaqGS.
Trading volume was reflecting a strong market reaction to the clinical update.
BCTX's 52-week range spans approximately $3.00 to $98.20, illustrating volatility tied to clinical progress and sector sentiment in biotech and cancer immunotherapy development.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.